Vaccentis
A clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines to improve patients’ chances of recovery from chronic and malignant diseases.
Vaccentis’ lead product VCC-001, which is in late-stage clinical development to treat non-metastatic renal cell carcinomas post nephrectomy. Vaccentis’ proprietary production methodology reduces complexity and allows for a three to four week vaccine delivery time, significantly shorter than normally seen with other personalized biologics.
Latest Vaccentis News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze